Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
-

Ratings ESG MSCI

Ratings NEURONES: Strengths and Weaknesses

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Highlights: NEURONES
  • The company's profit outlook over the next few years is a strong asset.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • With regards to fundamentals, the enterprise value to sales ratio is at 0.55 for the current period. Therefore, the company is undervalued.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Rating Financials

NEURONES SectorFrance

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

-

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

-

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

-

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

NEURONES SectorFrance

Global Valuation

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

-

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

-
More ratings

Rating Consensus

NEURONES SectorFrance

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

NEURONES SectorFrance

Visibility

-

Analysts' coverage

Financial estimates divergence

-

Analysts' recommendations divergence

Analysts' Target price divergence

-

Surprise rates

Rating Revisions

NEURONES SectorFrance

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
950M - -
234B
AA
81.48B
BB
80.51B
BBB
-
78.32B
AAA
55.4B
AAA
45.09B
A
34.54B
AAA
32.45B
AA
30.89B
AAA
Average 67.38B
AA
Weighted average by Cap.
AA
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!